Clinical Drug Investigation

, Volume 19, Supplement 2, pp 27–31 | Cite as

Clinical Pharmacology of Piroxicam-β-Cyclodextrin

Implications for Innovative Patient Care
Review Article

Abstract

The potential advantages of the piroxicam-β-cyclodextrin complex include more rapid absorption, more rapid onset of analgesia and improved gastrointestinal tolerability. These have been critically evaluated with reference to published work. In association with improved solubilisation, more rapid absorption of piroxicam has been clearly demonstrated, while its intrinsically long terminal half-life is maintained. There are several reports of improved gastrointestinal tolerability in comparison with conventional piroxicam: the clearest evidence for this has come from studies in healthy individuals, and it has not yet been established whether piroxicam-β-cyclodextrin causes less gastrointestinal haemorrhage than conventional piroxicam in patients treated in routine clinical practice. Although not totally inert, the carrier β-cyclodextrin appears to be safe for oral clinical use. Piroxicam-β-cyclodextrin is clearly an effective analgesic with a rapid onset of effect, representing a promising approach towards more effective and safe delivery of NSAIDs.

Keywords

Naproxen Piroxicam Ketoprofen Rapid Absorption Gastrointestinal Tolerability 

References

  1. 1.
    British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. London, 1999Google Scholar
  2. 2.
    Anonymous. Piroxicam. In: Dollery CT, editor. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991: 136-40Google Scholar
  3. 3.
    Cram DJ. The design of molecular hosts, guests and their complexes. J Inclusion Phenomena 1988; 6: 397–413CrossRefGoogle Scholar
  4. 4.
    Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 85: 1142–69PubMedCrossRefGoogle Scholar
  5. 5.
    Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14: 556–67PubMedCrossRefGoogle Scholar
  6. 6.
    Acerbi D, Bovis G, Carli F, et al. Biopharmaceutical optimisation of β-cyclodextrin inclusion compounds. Drug Invest 1990; 2Suppl. 4: 29–36CrossRefGoogle Scholar
  7. 7.
    Woodcock BG, Acerbi C, Merz, PG, et al. Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumatol Inflamm 1993; 12: 12–28PubMedGoogle Scholar
  8. 8.
    Acerbi D. Pharmacokinetic profile of piroxicam-β-cyclodextrin. Drug Invest 1990; 2Suppl. 4: 42–9CrossRefGoogle Scholar
  9. 9.
    Acerbi D, Lebacq Jr E, Rondelli I, et al. Rapid absorption profile of piroxicam from its β-cyclodextrin complex. Drug Invest 1990; 2Suppl. 4: 50–5CrossRefGoogle Scholar
  10. 10.
    Deroubaix X, Stockis A, Allemon AM, et al. Oral bioavailability of CHF 1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy subjects under single dose and steady-state conditions. Eur J Clin Pharmacol 1995;47: 531–6PubMedCrossRefGoogle Scholar
  11. 11.
    Acerbi D, Ventura P. β-Cyclodextrin-piroxicam: pharmacokinetic profile. J Drug Develop 1991; 4Suppl. 1: 17–9Google Scholar
  12. 12.
    Gerloczy A, Fonagy A, Keresztes P, et al. Absorption, distribution, excretion and elimination of orally administered 14C-β-cyclodextrin in rat. Arzneimittelforschung 1985; 35: 1042–7PubMedGoogle Scholar
  13. 13.
    Bauduin H, Famaey J-P. Comparison of the analgesic effects of β-cyclodextrin-piroxicam, sodium naproxen and potassium diclofenac utilizing the dental pain model. J Pharm Care Pain Symptom Control 1995: 3: 19–29CrossRefGoogle Scholar
  14. 14.
    Tamburro P, Galasso G. Studio clinico controllato sull’effetto antalgico del complesso piroxicam-beta-ciclodestrina nel dolore acuto musculo-scheletrico e/o articolare. Reumatologo 1989; 6: 237–41Google Scholar
  15. 15.
    Costa S, Mioli M, Ravaioli R, et al. Prostaglandin synthetase inhibitor piroxicam beta-cyclodextrin in the treatment of primary dysmenorrhea. Curr Ther Res 1987; 42: 156–64Google Scholar
  16. 16.
    Di Matteo L, Fratelli V, Oliani C, et al. La spalla dolorossa semplice: efficacia antalgica e tollerabilità del trattamento con il complesso piroxicam-beta-ciclodestrina. Arch Med Interna 1989; 41(4): 261–72Google Scholar
  17. 17.
    La Montagna G, Tirri G, Cacae E, et al. Quality of life assessment during six months of NSAID treatment [Gonarthrosis and Quality of Life (GOAL) Study]. Clin Exp Rheumatol 1998; 16: 49–54PubMedGoogle Scholar
  18. 18.
    Marcucci M, Panelli P, Cambini S. Clinical experience in the treatment of dental pain. Clin J Pain 1991; 7Suppl. 1: S72–6PubMedGoogle Scholar
  19. 19.
    Michelacci M, Boscarino G, Acerbi D, et al. Analgesic effect and pharmacokinetics of a piroxicam beta-cyclodextrin oral formulation in post-surgical pain. Clin Trials J 1990; 27: 176–86Google Scholar
  20. 20.
    Tamburro P, Galasso G. Efficacia e tollerabilità del piroxicam-beta-ciclodestrina nel trattamento del dolore muscoloscheletrico. Reumatologo 1989; 10: 104Google Scholar
  21. 21.
    Giacovazzo M, Marteletti V, Zaurito V, et al. Effetto antalgico acuto del complesso piroxicam-beta-ciclodestrina nel trattamento della cefalea. G Neuropsicofarmacol 1989; 11: 31–5Google Scholar
  22. 22.
    Dolci G, Ripari M, Pacifici L, et al. Evaluation of piroxicam-β-cyclodextrin, piroxicam, paracetamol and placebo in post-operative oral surgical pain. Int J Clin Pharm Res 1994; 14: 185–91Google Scholar
  23. 23.
    Nappi G, Manzoni GC, Oliani C. Piroxicam-β-cyclodextrin in the treatment of headache. Drug Invest 1990; 2Suppl. 4: 78–95Google Scholar
  24. 24.
    Tiengo M. Review of the analgesic effects of piroxicam-β-cyclodextrin. Drug Invest 1990; 2Suppl. 4: 61–6CrossRefGoogle Scholar
  25. 25.
    Passeri M. Piroxicam-β-cyclodextrin in rheumatology. Drug Invest 1990; 2Suppl. 4: 86–8CrossRefGoogle Scholar
  26. 26.
    Costa S, Zinelli G, Bufalino L. Piroxicam-β-cyclodextrin in the treatment of dysmenorrhoea. Drug Invest 1990; 2Suppl. 4: 73–8CrossRefGoogle Scholar
  27. 27.
    Wyss V, Ganzit GP. Piroxicam-β-cyclodextrin in sports medicine and traumatology. Drug Invest 1990; 2Suppl. 4: 67–72CrossRefGoogle Scholar
  28. 28.
    Lee CR, Balfour JA. Piroxicam-β-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. Drugs 1994; 48: 907–29PubMedCrossRefGoogle Scholar
  29. 29.
    Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104(3A): 30S–34SPubMedCrossRefGoogle Scholar
  30. 30.
    Santucci L, Fiorucci S, Chiucciu S, et al. Placebo-controlled comparison of piroxicam-β-cyclodextrin, piroxicam and indomethacin on gastric potential difference and mucosal injury in humans. Dig Dis Sci 1992; 37: 1825–32PubMedCrossRefGoogle Scholar
  31. 31.
    Muller P, Simon B. Vergleichende endoskopische Untersuchung zur gastroduodenalen Vertraglichkeit von Piroxicam-β-cyclodextrin vs Piroxicam. Z Rheumatol 1997; 56: 76–9PubMedCrossRefGoogle Scholar
  32. 32.
    Nervetti A, Ambanelli U, Ugolotti G. Assessment of gastric mucosal damage by a new inclusion complex of piroxicam with β-cyclodextrin: a functional study by a scintigraphic method. J Drug Dev 1991; 4Suppl. 1: 39–42Google Scholar
  33. 33.
    Warrington S, Debbas N, Farthing M, et al. Piroxicam-β-cyclodextrin: effects on gastrointestinal blood loss and gastric mucosal appearance in healthy men. Int J Tissue React 1991; 13: 243–8PubMedGoogle Scholar
  34. 34.
    Patoia L, Clausi G, Farroni F, et al. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam β-cyclodextrin, piroxicam and placebo administration. Eur J Clin Pharmacol 1989; 36: 599–604PubMedCrossRefGoogle Scholar
  35. 35.
    Varela P, Amorim I, Massa A, et al. Piroxicam-β-cyclodextrin and photosensitivity reactions. Contact Dermatitis 1998; 38: 229PubMedCrossRefGoogle Scholar
  36. 36.
    Umile A. Piroxicam-beta-cyclodextrin and photosensitivity reactions [letter and reply]. Contact Dermatitis 1999; 40: 340–2PubMedCrossRefGoogle Scholar
  37. 37.
    Christian AE, Haynes MP, Phillips MC, et al. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 1997; 38: 2264–72PubMedGoogle Scholar
  38. 38.
    Totterman AM, Schipper NG, Thompson DO, et al. Intestinal safety of water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal Caco-2 cells. J Pharm Pharmacol 1997; 49: 43–8PubMedCrossRefGoogle Scholar
  39. 39.
    Catala I, Domingo N, Juste C, et al. Effect of beta-cyclodextrin dietary supplementation on biliary proteins and their resulting cholesterol nucleating activity in pigs. Biochem Biophys Acta 1998; 1394: 74–84PubMedCrossRefGoogle Scholar
  40. 40.
    Toyoda K, Shoda T, Uneyama C, et al. Carcinogenicity study of beta-cyclodextrin in F344 rats. Food Chem Toxicol 1997; 35: 331–6PubMedCrossRefGoogle Scholar
  41. 41.
    Singh G, Ramey DR, Morfield D, et al. Gastrointestinal complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.DDS Medicines Research LimitedNinewells Hospital and Medical SchoolDundeeScotland

Personalised recommendations